This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Why Is Jazz (JAZZ) Up 1.8% Since Last Earnings Report?
by Zacks Equity Research
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Strength Seen in Jazz (JAZZ): Can Its 6.6% Jump Turn into More Strength?
by Zacks Equity Research
Jazz (JAZZ) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Jazz Pharma (JAZZ) Q1 Earnings Beat, Sales Miss, Stock Down
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) reports mixed first-quarter 2021 results as earnings beat estimates while sales miss the same. Shares down
Jazz Pharmaceuticals (JAZZ) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Jazz (JAZZ) delivered earnings and revenue surprises of 6.23% and 0.16%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Alzheimer's Disease: 5 Stocks on Biotech Radars
by Kevin Cook
While Biogen rides a big-cap rollercoaster, a few small players are creating better trading opps.
JAZZ vs. ZTS: Which Stock Is the Better Value Option?
by Zacks Equity Research
JAZZ vs. ZTS: Which Stock Is the Better Value Option?
Enhance Your Portfolio With These 6 Low Price-to-Book Stocks
by Kinjel Shah
P/B ratio is emerging as a convenient tool for identifying low-priced stocks that have high growth prospects
Cannabis On a Roll: Guide to ETF Investing
by Sanghamitra Saha
Shares of cannabis-related stocks and ETFs continue to be in good shape after a solid run last year.
JAZZ's Xywav sNDA for Hypersomnia Gets FDA Priority Review
by Zacks Equity Research
JAZZ focuses on expanding label of its recently approved sleep drug, Xywav - a low sodium-formulation of Xyrem.
Jazz's (JAZZ) Vyxeos Gets FDA Nod for Pediatric Leukemia
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) gets FDA approval for label expansion of its cancer drug, Vyxeos, in pediatric patients with newly-diagnosed therapy-related acute myeloid leukemia.
Why Is Jazz (JAZZ) Down 5.6% Since Last Earnings Report?
by Zacks Equity Research
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
New Strong Sell Stocks for March 23rd
by Zacks Equity Research
BZUN, EQR, FRPT, JAZZ, and SPTN have been added to the Zacks Rank #5 (Strong Sell) List on March 23, 2021
New Strong Sell Stocks for March 18th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Jazz Pharma (JAZZ) Q4 Earnings Miss, 2021 Sales View Dull
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) reports mixed fourth-quarter 2020 results as earnings miss estimates while sales beat the same. Shares down.
Drug/Biotech Stock Q4 Earnings on Feb 23: JAZZ, ARNA & More
by Kinjel Shah
Let us take a look at five small biotech companies, JAZZ, ARNA, HALO, EPZM, ESPR, which are gearing up for their earnings release.
Should You Invest in Marijuana Stocks & ETFs Now?
by Neena Mishra
CNBC's cannabis expert Tim Seymour discusses the outlook for the industry.
Biotech Stock Roundup: Q4 Results of BMY, REGN, BIIB & Other Regulatory Updates
by Zacks Equity Research
Earnings of leading biotechs like Biogen (BIIB), Gilead (GILD) and Regeneron (REGN) dominate last week's headlines in the biotech sector.
Cannabis Stocks Rise on Hopes of Federal Legalization in US
by Zacks Equity Research
Cannabis stocks seem poised to gain on hopes of removal of the federal ban on cannabis products under the new administration.
New Strong Sell Stocks for February 10th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Cannabis ETFs Spike on Jazz-GW Pharma Deal
by Sweta Killa
Jazz Pharmaceuticals (JAZZ) agreed to buy cannabinoid drug company GW Pharmaceuticals (GWPH) for $7.2 billion in cash and stock that has strengthened the bullish case for the cannabis industry.
Jazz (JAZZ) Initiates BLA Submission for Leukemia Candidate
by Zacks Equity Research
Jazz (JAZZ) initiates the submission of a BLA to the FDA for the marketing approval of JZP-458 for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma.
JAZZ's Zepzelca Combo SCLC Study Fails, Drug Still Promising
by Zacks Equity Research
JAZZ announces the failure of a combination regimen of SCLC drug, Zepzelca, to meet primary endpoint in a late-stage study. However, overall study data seems promising for the drug. Stock up.
Jazz (JAZZ) Down 3.7% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Can Value Investors Consider Jazz Pharmaceuticals (JAZZ) Stock?
by Zacks Equity Research
Is Jazz Pharmaceuticals (JAZZ) a great pick from the value investor's perspective right now? Read on to know more.
Jazz Pharma (JAZZ) Beats on Q3 Earnings, Ups Sales Guidance
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) reports better-than-expected third-quarter 2020 earnings and revenues and ups its sales guidance for 2020.